Reimagining cholinergic therapy for Alzheimer's disease

Area of Science:

• Neuroscience
• Pharmacology
• Gerontology

Background:

• Cholinergic neurotransmission enhancement via cholinesterase inhibitors is the primary treatment for Alzheimer's disease (AD) cognitive and behavioral symptoms.
• Four of six approved AD therapies are acetylcholinesterase inhibitors, highlighting the importance of the cholinergic system.
• Memantine and aducanumab represent other therapeutic strategies targeting different pathologies in AD.

Purpose of the Study:

• To provide an updated review of the basal forebrain cholinergic system in relation to cognition and AD therapy.
• To discuss the origin, mechanism, clinical effects, advantages, and limitations of cholinergic therapy for AD.
• To explore novel therapeutic avenues, including M1 muscarinic receptor agonists and nerve growth factor pathways.

Main Methods:

• Review of current literature on cholinergic system function and AD.
• Analysis of clinical studies on cholinesterase inhibitor efficacy and disease-modifying potential.
• Examination of emerging research on muscarinic receptors and nerve growth factor in AD.

Main Results:

• Cholinergic therapy remains central to AD symptom management, with evidence suggesting long-term efficacy and potential disease-modifying effects of cholinesterase inhibitors.
• Novel M1 muscarinic receptor agonists show disease-modifying potential.
• A newly discovered nerve growth factor pathway is implicated in basal forebrain maintenance and AD deregulation.

Conclusions:

• Cholinergic therapy is crucial for managing AD symptoms, with cholinesterase inhibitors offering symptomatic relief and potential disease modification.
• Newer agents like selective M1 agonists and understanding nerve growth factor pathways offer promising avenues for future AD treatments.
• Optimizing current cholinergic approaches and developing novel strategies are essential to enhance clinical effects and slow disease progression in AD.